Monday, Aug 03, 2020 | Last Update : 03:49 PM IST

132nd Day Of Lockdown

Maharashtra44122827680915576 Tamil Nadu2576131964834132 Andhra Pradesh158764828861474 Delhi1376771233174004 Karnataka134819577252496 Uttar Pradesh92921533571730 West Bengal75516527301678 Telangana6766048609551 Gujarat63675466892482 Bihar5727036637322 Rajasthan4441031216706 Assam4290532385105 Haryana3651929690433 Odisha3491321955236 Madhya Pradesh3353523550886 Kerala259121446383 Jammu and Kashmir2141613127396 Punjab1785311466423 Jharkhand121884513115 Chhatisgarh9608699158 Uttarakhand7593443786 Goa6530466853 Tripura5248346323 Puducherry3806230952 Manipur283117377 Himachal Pradesh2654150813 Arunachal Pradesh19359693 Nagaland19356484 Chandigarh111769819 Meghalaya8742645 Sikkim6582891 Mizoram4702580
  Science   11 Jul 2020  DGCI okays Itolizumab drug for restricted emergency use on COVID patients

DGCI okays Itolizumab drug for restricted emergency use on COVID patients

PTI
Published : Jul 11, 2020, 6:53 pm IST
Updated : Jul 11, 2020, 6:53 pm IST

Biocon, a domestic biopharmaceutical company, has been manufacturing and marketing the drug.

Representational image.
 Representational image.

New Delhi: Based on clinical trials data, India's drug regulator has approved itolizumab, used to treat skin condition psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, the Union health ministry said on Saturday.

Considering the unmet medical needs in COVID-19, Drugs Controller General of India (DCGI) Dr V G Somani had on Friday approved itolizumab injection for use in the treatment of coronavirus patients.

 

Biocon, a domestic biopharmaceutical company, has been manufacturing and marketing Itolizumab, a monoclonal antibody drug, for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under the brand name Alzumab, the health ministry said.

"This indigenous drug has now been repurposed for COVID-19," it said in a statement.

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office.

"After detailed deliberation and taking into account the recommendations of the committee, the DCGI has decided to grant permission to market the drug under restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19," it said.

 

The use of the medicine is subject to some conditions including requirement of informed consent of patients, a risk management plan and usage only in hospital setup.

The average cost of treatment with this indigenous drug Itolizumab is lesser than other medicines which are part of investigational therapies indicated in the health ministry's Clinical Management Protocols for COVID-19.

Tags: coronavirus drug, coronavirus drug trial, coronavirus (covid-19), itolizumab